General information about company							
Name of The Company	SANDU PHARMACEUTICALS LIMITED						
BSE Scrip Code	524703						
NSE Symbol							
MSE Symbol							
Date of Start of Financial Year	01-04-2023						
Date of End of Financial Year	31-03-2024						
Reporting Period	First half yearly						
Date of Start of Reporting Period	01-04-2023						
Date of End of Reporting Period	30-09-2023						
Level of rounding to be used in disclosing related party transactions	Lakhs						
Whether the company has any related party?	Yes						
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes						

1 of 4

[I] We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public

(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of bank's staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appropriated for a fixed lenure.

(III) Whether the company is a 'high value debt listed entity' according to regulation 15 (1A)?

(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?

(b) If answer to above question is No, please explain the reason for not complying.

2 of 4

	Related party transactions																
													Additional disclosure of related party trai relates to loans, inter-corporate depc entity/subsidiary. These details need to t trai				
Sr No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty					Value of the related			In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter- corporate deposits, advances or investments				
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary	Type of related party transaction	Details of other related party transaction	f party transaction as approved	Remarks on approval by audit committee	Value of transaction during the reporting period	Opening balance	Closing	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	N: ad in de in
1	M/s Sandu Pharmaceuticals Ltd.	AAACS6291G	M/s Sandu Brothers Pvt. Ltd	AADCS9226L	Entities in which KMP are Interested	Purchase of goods or services			Purchase of goods or services	1008.22784	296.95963	124.26788					
2	M/s Sandu Pharmaceuticals Ltd.	AAACS6291G	M/s Sandu Brothers Pvt. Ltd	AADCS9226L	Entities in which KMP are Interested	Any other transaction	ROYALTY		Any other transaction	59.5548	0	0					
3	M/s Sandu Pharmaceuticals Ltd.	AAACS6291G	Mr. Umesh Bhaskar Sandu	ABWPS9336G	Entities in which KMP are Interested	Remuneration			Remuneration	42.24	7.04	7.04					
4	M/s Sandu Pharmaceuticals Ltd.	AAACS6291G	M/s Sandu Brothers Pvt. Ltd	AADCS9226L	Entities in which KMP are Interested	Sale of goods or services			Sale of goods or services	41.16047	0	0					
5	M/s Sandu Pharmaceuticals Ltd.	AAACS6291G	Rakesh Parekh	AMYPP0706G	Key management personnel of entity or parent	Remuneration			Remuneration	5.4624	-0.71159	-0.9104					
6	M/s Sandu Pharmaceuticals Ltd.	AAACS6291G	Pratika Mhambray	CTQPS2943K	Key management personnel of entity or parent	Remuneration			Remuneration	3.3	-55	0.56					
7	SANDU PHARMACEUTICALS LIMITED	AAACS6291G	AKSHATH FINVEST AND PROPERTIES PRIVATE LIMITED	AABCA2004Q	Promoter	Sale of goods or services			Sale of goods or services	23.72803	-9.94708	14.13232					
Total value of transaction during the reporting										1183.67354							

14-11-2023, 17:05 3 of 4

4 of 4